Schering-Plough has expanded its presence in China by establishing Shanghai Schering-Plough Pharmaceutical Co. Ltd. A wholly-owned operation based in Shanghai, the unit was formed through the acquisition of shares of its former joint venture partners. SP entered into an agreement in 1994 with Shanghai Pharmaceutical Industry Co., Ltd. and Shanghai Pharmaceutical Group Co., Ltd., to manufacture, market and distribute allergy and skincare products.
   
“The actions announced today are part of Schering-Plough’s long-term global geographic expansion strategy,” said Fred Hassan, chairman and chief executive officer of SP. “Investing in the Asia-Pacific Region, and especially China, represents another step in our journey to transform Schering-Plough into a global high-performance health care company. With a long-term presence in China, Schering-Plough now takes a significant step forward in its strategic development to further build growth and strength in this important market.”
   
SP in China serves Chinese health care professionals, customers and other stakeholders in the areas of allergy/respiratory, cardiovascular, central nervous system, skin care, oncology, infectious diseases, and women’s health.